Insulin Pumps and Hybrid Close Loop Systems Within Hospital: A Scoping Review and Practical Guidance From the Joint British Diabetes Societies for Inpatient Care.


Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
05 2023
Historique:
medline: 3 5 2023
pubmed: 3 12 2022
entrez: 2 12 2022
Statut: ppublish

Résumé

This article is the second of a two-part series providing a scoping review and summary of the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) guidelines on the use of diabetes technology in people with diabetes admitted to hospital. The first part reviewed the use of continuous glucose monitoring (CGM) in hospital. In this article, we focus on the use of continuous subcutaneous insulin infusion (CSII; insulin pumps) and hybrid closed-loop systems in hospital. JBDS-IP advocates enabling people who can self-manage and are willing and capable of using CSII to continue doing so as they would do out of hospital. CSII should be discontinued if the individual is critically ill or hemodynamically unstable. For individuals on hybrid closed-loop systems, the system should be discontinued from auto-mode, and may be used individually (as CGM only or CSII only, if criteria are met). Continuing in closed-loop mode may only be done so under specialist guidance from the Diabetes Team, where the diabetes teams are comfortable and knowledgeable about the specific devices used. Health care organizations need to have clear local policies and guidance to support individuals using these wearable technologies, and ensure the relevant workforce is capable and skilled enough to ensure their safe use within the hospital setting.

Identifiants

pubmed: 36458697
doi: 10.1177/19322968221137335
pmc: PMC10210119
doi:

Substances chimiques

Hypoglycemic Agents 0
Blood Glucose 0
Insulin 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-634

Références

J Diabetes Sci Technol. 2012 Sep 01;6(5):995-1002
pubmed: 23063024
Diabet Med. 2022 Feb;39(2):e14744
pubmed: 34811800
Acta Diabetol. 2021 Jul;58(7):967-969
pubmed: 33864123
Endocr Pract. 2009 Jul-Aug;15(5):415-24
pubmed: 19491071
Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-188
pubmed: 33515493
Front Pediatr. 2021 Apr 29;9:625390
pubmed: 33996680
Diabetes Care. 2018 Aug;41(8):1579-1589
pubmed: 29936424
J Diabetes Sci Technol. 2016 Nov 1;10(6):1360-1371
pubmed: 27301982
Lancet Diabetes Endocrinol. 2019 May;7(5):368-377
pubmed: 30935872
J Clin Endocrinol Metab. 2002 Mar;87(3):978-82
pubmed: 11889147
Diabet Med. 2018 Aug;35(8):992-996
pubmed: 29923215
J Diabetes Sci Technol. 2020 Nov;14(6):1035-1064
pubmed: 32985262
Curr Diab Rep. 2021 Jan 15;21(2):7
pubmed: 33449214
N Engl J Med. 2018 Aug 09;379(6):547-556
pubmed: 29940126
Endocr Pract. 2014 May;20(5):463-89
pubmed: 24816754
Diabet Med. 2015 Nov;32(11):1453-9
pubmed: 26213236
Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124
pubmed: 27836235
Diabet Med. 2019 Mar;36(3):269-278
pubmed: 30098219
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-2128
pubmed: 35690958
AACE Clin Case Rep. 2021 Jan 06;7(3):184-188
pubmed: 34095484
Diabetes Care. 2022 Jan 1;45(Suppl 1):S244-S253
pubmed: 34964884
Diabetes Technol Ther. 2018 Jul;20(7):501-505
pubmed: 29958022
Kidney Int. 2019 Sep;96(3):593-596
pubmed: 31133457
J Diabetes Sci Technol. 2014 May;8(3):473-8
pubmed: 24876608
Endocrinol Metab (Seoul). 2021 Apr;36(2):240-255
pubmed: 33789033
Diabet Med. 2016 Sep;33(9):1253-9
pubmed: 26927202
J Diabetes Sci Technol. 2022 Nov;16(6):1575-1576
pubmed: 36036511

Auteurs

Parizad Avari (P)

Department of Diabetes and Endocrinology, Imperial College Healthcare NHS Trust, London, UK.
Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

Alistair Lumb (A)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.

Daniel Flanagan (D)

Department of Endocrinology, University Hospital Plymouth, Plymouth, UK.

Gerry Rayman (G)

Ipswich Diabetes Centre, East Suffolk and North East Essex Foundation Trust, Ipswich, UK.

Shivani Misra (S)

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

Pratik Choudhary (P)

Diabetes Research Centre, University of Leicester, Leicester, UK.

Ketan Dhatariya (K)

Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH